The two cell lines do not seem to respond similarly to the assays conducted after downregulating TRMT6/TRMT61A expression, which could reflect that the underlying mechanisms for BLCA pathogenesis differ in the two systems. The gene discussed is TRMT6; the disease is bladder transitional cell carcinoma.